Retina/Vitreous News

The FDA granted rare pediatric disease and fast track designations to gildeuretinol, an investigational oral therapy for the treatment of Stargardt disease, according to a press release from Alkeus Pharmaceuticals.

The European Commission has approved Opuviz 40 mg/mL solution, a biosimilar referencing Eylea, according to a press release from Samsung Bioepis and Biogen.

CHICAGO — In this video, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses study results presented at the AAO meeting on ONL1204 from ONL Therapeutics.

Adverum Biotechnologies reported positive 52-week data from the phase 2 LUNA trial as well as long-term follow-up results from the OPTIC trial of Ixo-vec in patients with wet age-related macular degeneration.

Evaluations of diabetic retinopathy severity appeared comparable with ultra-widefield and 7-field imaging, suggesting ultra-widefield imaging can be used in future longitudinal studies without bias, according to a cross-sectional study.

CHICAGO — In this video, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses controversies surrounding the use of complement inhibitors for the treatment of geographic atrophy.

BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Matteo Forlini, MD, discusses a Vit-Buckle Society session on surgical challenges.

NEW YORK — In this Healio Video Perspective from OSN New York Retina, Rishi P. Singh, MD, FASRS, of Cleveland Clinic Florida discusses the need for anti-VEGF biosimilars and the possibility of on-label bevacizumab.

A decrease in the number of orbital decompression surgeries in patients with thyroid eye disease may be attributed to the introduction of teprotumumab treatment, according to a study published in Canadian Journal of Ophthalmology.